Eli Lilly said on Friday the U.S. Food and Drug Administration approved its eczema drug for use in adults and children above 12 years old. The drug, which is an injectable medicine and branded Ebglyss,

Sold under the brand names Mounjaro and Zepbound, tirzepatide has been an incredible growth driver for Eli Lilly. In 2022 -- the year it was first approved in the U.S. -- some analysts predicted that it could generate as much as $25 billion in peak sales and become one of the best-selling drugs in the industry's history.

Eli Lilly and Company is expanding its manufacturing footprint in Ireland with a $1.8B investment to boost production of biologic active ingredients.

Eli Lilly is investing $1.8 billion across two manufacturing sites in Ireland to boost production of its hugely popular obesity drug and a newly approved treatment for Alzheimer's, the drugmaker said on Thursday.

Demand for Eli Lilly’s Zepbound and Mounjaro has outstripped supply over the last year, forcing the company to invest heavily to increase production.

The investments are part of Lilly's ongoing commitment to expand production for its top-selling diabetes and obesity drugs

The doubling of Lilly’s investment in the new plant points to its confidence in its portfolio of Alzheimer’s drugs. Manufacturing the active ingredient for those medicines wil